



18/07/2023

## **NEW FACTORIES AND TECHNOLOGIES IN THE USA FOR CLAYENS GROUP**

Clayens is accelerating its development in North America with the acquisition of 13 manufacturing plants in the USA and Mexico since January 2023. These acquisitions enable Clayens to strengthen its presence in North America by diversifying its client portfolio and integrating new technologies, particularly in the healthcare sector.

Among these acquisitions, three new plants located near Chicago (Crystal Lake, IL) and near Boston (East Providence, RI, and Wallingford, CT) are reinforcing the existing Clayens Healthcare footprint in North America, along with the Mexican site in Torreón and its ISO7 cleanroom. All these plants are ISO 13485 certified and FDA registered.

The Crystal Lake (USA) and Torreón (Mex) plants are specialized in the production of pharmaceutical products such as primary and secondary packaging, including pre-filled and non-pre-filled syringes, Tubs, Nests, and sharp containers. The new manufacturing capacity of the Crystal Lake plant is significant, with nearly 40,000 square meters of ISO8 cleanrooms and around 88 injection presses. Apart from their classified environments (ISO8 for Crystal Lake and ISO7 for Torreón), the distinctive feature of these sites is the high level of automation in their production processes.

The two other plants near Boston are specialized in medical devices, including surgical kits, diagnostic kits, imaging, cardiology, and dental products. Their processing technologies are quite different. The East Providence plant, equipped with an ISO8 cleanroom, is focused on injection technologies, including micro-injection (52 injection machines ranging from 7 to 300 tons), overmolding, and the manufacturing of bioresorbable PLA implants. The Wallingford plant is specialized in machining with 38 CNC machines. Both of these plants are fit to work on low-volume productions.

These recent acquisitions bring a new dimension to Clayens Group, which now employs 5,500 people, generates a turnover of 700 million euros, and has an industrial base of 33 plants worldwide. *"The Healthcare division, which currently accounts for approximately 20% of the group's activities is now representing 10 manufacturing sites in Europe and North America. The healthcare sector is clearly one of our strategic focus. Our recent acquisitions rank us among the major players in precision plastic parts manufacturing for the healthcare sector in Europe and North America."* stated Brice Collet-Beillon, Senior Executive VP EMEA at Clayens.



18/07/2023

### About Clayens :

CLAYENS Healthcare represents the Healthcare division of Clayens Group and supports healthcare industry players (medical devices, pharmaceuticals, and diagnostics) in the development, industrialization, and manufacturing of custom-made medical devices and plastic components in compliance with international regulatory standards.

CLAYENS Healthcare offers a comprehensive service from R&D to production, including industrialization, qualification, validation, and regulatory support. With a presence in 9 countries, Clayens Group has nearly 5,500 employees and 33 manufacturing sites. The Group's 9 cleanrooms are located in France (ISO7), the USA (ISO8), Mexico (ISO7), and Poland (ISO7).

For more information, please visit: <https://www.clayens-np.com/en/taxonomy/term/23>.

### Contact us

Brian FLYNN - Executive Vice President Clayens US

 ( 347 ) 526-3019

 brian.flynn@clayens.com



*East Providence*



*Crystal Lake*

